Financial Performance - For the fiscal year ending June 30, 2024, the revenue was approximately HKD 94.8 million, a decrease of about 25.1% compared to HKD 126.6 million for the fiscal year ending June 30, 2023[1]. - The profit before tax for the fiscal year ending June 30, 2024, was approximately HKD 39.2 million, down approximately 33.2% from HKD 58.7 million for the previous year[1]. - The profit attributable to equity holders for the fiscal year ending June 30, 2024, was approximately HKD 30.9 million, a decrease of about 34.1% compared to HKD 46.9 million for the fiscal year ending June 30, 2023[1]. - The basic earnings per share for the fiscal year ending June 30, 2024, was HKD 0.0773, compared to HKD 0.1173 for the previous year[2]. - The group reported a net profit of HKD 30.9 million for the fiscal year ending June 30, 2024, compared to HKD 46.9 million for the previous year[3]. - Total revenue for the group in 2024 was HKD 94,787 thousand, a decline of 25% compared to HKD 126,558 thousand in 2023[11]. - Revenue from healthcare staffing solutions decreased to HKD 77,346 thousand in 2024, down 25% from HKD 102,998 thousand in 2023[11]. - Other income in 2024 was HKD 1,508 thousand, significantly lower than HKD 8,997 thousand in 2023, reflecting a decline of approximately 83.2%[13]. - The net loss from other losses was approximately HKD 1.3 million, compared to a loss of HKD 1.0 million in the previous year[42]. Dividends - The proposed final dividend for the fiscal year ending June 30, 2024, is HKD 0.025 per share, down from HKD 0.0375 per share for the previous year[1]. - The company declared a final dividend of HKD 15,000,000 for the year, impacting retained earnings[6]. - The company plans to pay an interim dividend of HKD 20,123,000 (HKD 5.00 per share) for the year 2024[21]. - The company proposed a final dividend of HKD 2.50 per share for the current year, compared to HKD 3.75 in the previous year[71]. - Total dividends for the year amount to HKD 7.50 per share, unchanged from the previous year[72]. Assets and Liabilities - Total assets as of June 30, 2024, were HKD 318.1 million, a decrease from HKD 346.8 million as of June 30, 2023[4]. - Total liabilities as of June 30, 2024, were HKD 99.7 million, down from HKD 124.5 million as of June 30, 2023[5]. - The total outstanding bank financing was approximately HKD 108,400,000 as of June 30, 2024, with HKD 45,300,000 remaining undrawn[49]. - The group reported bank borrowings of HKD 63,119,000 in 2024, a decrease from HKD 65,525,000 in 2023[30]. - The debt-to-capital ratio was approximately zero as of June 30, 2024, consistent with the previous year[53]. Employee Expenses - The group’s employee benefit expenses decreased to HKD 26.0 million from HKD 38.7 million year-on-year[2]. - Employee benefits expenses for the year were approximately HKD 26.0 million, down from HKD 38.7 million for the year ended June 30, 2023[43]. - Employee benefits expenses decreased from HKD 38,723,000 in 2023 to HKD 26,019,000 in 2024, a reduction of approximately 32.9%[15]. - The company's retirement benefit costs for the defined contribution plan decreased from HKD 1,403,000 in 2023 to HKD 1,219,000 in 2024, a decrease of approximately 13.1%[15]. - The company employed a total of 55 employees as of June 30, 2024, down from 62 employees in 2023[59]. Market and Business Strategy - The company continues to focus on expanding its healthcare staffing solutions and vaccination services in Hong Kong, aiming for market growth[7]. - The group aims to strengthen its core business and become a more recognized market leader in response to the increasing demand for healthcare staffing solutions[39]. - The group plans to adopt a prudent capital policy to safeguard shareholder financial interests amid uncertainties in the capital market for 2025 and 2026[39]. - The group continues to focus on providing healthcare staffing solutions and related services, adapting to market demands and regulatory changes[11]. Financial Reporting and Governance - The company has implemented new accounting standards effective from July 1, 2023, which may influence future financial reporting[9]. - The company has not adopted any new or revised Hong Kong Financial Reporting Standards that would significantly impact the consolidated financial statements in the foreseeable future[10]. - The company has adhered to the corporate governance code and standards throughout the year[65]. - The board of directors will continue to review the effectiveness of the corporate governance structure, including the separation of the roles of Chairman and CEO[67]. - The audit committee, consisting of three independent non-executive directors, has approved the nature and scope of the statutory audit for the year[68]. Share Capital and Options - The group issued a total of 402,460,000 ordinary shares as of June 30, 2024, including 2,460,000 shares issued under the share incentive plan[28]. - The company has 8,900,000 unexercised stock options available for exercise at an average exercise price of HKD 1.192 per option[32]. - The stock option plan allows for a maximum of 10% of the total issued shares to be granted, with no new options issued during the current year[33]. - The company granted a total of 2,460,000 reward shares under the share reward plan to 21 participants, which will be implemented through a trustee[34]. - The total number of shares issued under the share reward plan as of June 30, 2024, is 2,380,000, representing 0.59% of the total issued shares[35]. Future Outlook - The company will hold its annual general meeting on November 28, 2024[70]. - The company will issue its annual report, which includes all information required by listing rules, in due course[74].
百本医护(02293) - 2024 - 年度业绩